Aytu BioPharma, Inc (AYTU) shareholders
Close on Nov 17, 2026Market cap $28.91MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Nantahala Capital Management, LLC Joint filing with Harkey Wilmot B. (14.40%), Mack Daniel (14.40%) | 1,086,812 | 14.40% | 13D (active) amendment | Jun 6, 2025 |
| Lytton Laurence W Joint filing with Lytton-Kambara Foundation (8.80%) | 1,071,351 | 9.99% | 13G (passive) amendment | Dec 31, 2025 |
| Stonepine Capital Management, LLC Joint filing with Stonepine Capital, L.P. (9.90%), Stonepine GP, LLC (9.90%) and 1 more | 906,063 | 9.90% | 13G (passive) amendment | Jun 30, 2025 |
| Kanen David Joint filing with Kanen Wealth Management LLC (10.30%), Philotimo Fund, LP (6.90%) | 635,073 | 10.30% | 13G (passive) amendment | May 15, 2025 |
| AWM Investment Company, Inc. | 619,574 | 5.80% | 13G (passive) amendment | Dec 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of AYTU | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Nantahala Capital Management, LLC | 2,173,624 | 20.00% | $4.67M | +1,086,812 | 0.08% |
| Stonepine Capital Management, LLC | 912,921 | 8.40% | $1.96M | +120,632 | 1.11% |
| AWM Investment Company, Inc. | 619,574 | 5.70% | $1.33M | – | 0.12% |
| Vanguard Capital Management LLC | 261,146 | 2.40% | $561.46K | – | 0.00% |
| Crown Advisors Management, Inc. | 200,000 | 1.84% | $430.00K | +55,000 | 0.24% |
| Diadema Partners LP | 148,546 | 1.37% | $319.37K | −204,531 | 0.04% |
| Two Sigma Investments, LP | 105,326 | 0.97% | $226.45K | −16,647 | 0.00% |
| Renaissance Technologies LLC | 104,823 | 0.96% | $225.37K | +11,100 | 0.00% |
| Geode Capital Management, LLC | 93,647 | 0.86% | $201.37K | +1,011 | 0.00% |
| Citadel Advisors LLC | 49,414 | 0.45% | $106.24K | +12,573 | 0.00% |
| Vanguard Fiduciary Trust Co | 47,048 | 0.43% | $101.15K | – | 0.00% |
| Dimensional Fund Advisors LP | 45,326 | 0.42% | $97.45K | +1,741 | 0.00% |
| Persistent Asset Partners Ltd | 37,984 | 0.35% | $81.67K | −54,913 | 0.02% |
| Northern Trust Corp | 27,925 | 0.26% | $60.04K | +8,756 | 0.00% |
| Bellevue Asset Management, LLC | 25,013 | 0.23% | $53.78K | – | 0.02% |
| BlackRock, Inc. | 22,793 | 0.21% | $49.01K | – | 0.00% |
| XTX Topco Ltd | 21,416 | 0.20% | $46.04K | −166 | 0.00% |
| Acadian Asset Management LLC | 10,237 | 0.09% | $22.00K | – | 0.00% |
| Daytona Street Capital LLC | 10,000 | 0.09% | $22.35K | – | 0.02% |
| UBS Group AG | 2,377 | 0.02% | $5.11K | +714 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 38 | 5M | 45.3% | 3 / 12 | 5 / 2 | 1M | 0M |
| Q1 2026 | 37 | 4M | 35.9% | 6 / 9 | 5 / 5 | 1M | 0M |
| Q4 2025 | 39 | 4M | 34.7% | 9 / 9 | 6 / 3 | 0M | 0M |
| Q3 2025 | 33 | 4M | 32.9% | 6 / 9 | 3 / 4 | 1M | 1M |
| Q2 2025 | 32 | 3M | 31.4% | 7 / 5 | 6 / 5 | 2M | 0M |
| Q1 2025 | 31 | 2M | 17.3% | 7 / 6 | 2 / 5 | 0M | 0M |
| Q4 2024 | 29 | 2M | 17.3% | 7 / 5 | 5 / 2 | 0M | 0M |
| Q3 2024 | 24 | 2M | 18.9% | 1 / 4 | 8 / 3 | 0M | 1M |
| Q2 2024 | 27 | 3M | 28.9% | 3 / 7 | 6 / 3 | 1M | 0M |
| Q1 2024 | 27 | 2M | 16.5% | 6 / 7 | 5 / 1 | 0M | 1M |
| Q4 2023 | 22 | 3M | 26.4% | 2 / 9 | 6 / 2 | 1M | 0M |
| Q3 2023 | 22 | 2M | 15.9% | 3 / 5 | 6 / 2 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
15 funds held AYTU in Q2 2026, 76% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of AYTU | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 169,000 | 1.56% | $363.35K | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 92,146 | 0.85% | $198.11K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 50,229 | 0.46% | $115.02K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 11,929 | 0.11% | $27.32K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 9,757 | 0.09% | $22.34K | 0.00% | May 31, 2026 |
| U.S. Vector Equity Portfolio | 5,481 | 0.05% | $12.22K | 0.00% | Jul 31, 2026 |
| Dimensional US Sustainability Core 1 ETF | 4,805 | 0.04% | $10.72K | 0.00% | Jul 31, 2026 |
| U.S. Sustainability Core 1 Portfolio | 4,640 | 0.04% | $10.35K | 0.00% | Jul 31, 2026 |
| Dimensional U.S. Small Cap ETF | 4,402 | 0.04% | $9.82K | 0.00% | Jul 31, 2026 |
| Dimensional U.S. Core Equity 2 ETF | 4,122 | 0.04% | $9.19K | 0.00% | Jul 31, 2026 |
| U.S. Core Equity 1 Portfolio | 4,100 | 0.04% | $9.14K | 0.00% | Jul 31, 2026 |
| Dimensional US Core Equity 1 ETF | 2,147 | 0.02% | $4.79K | 0.00% | Jul 31, 2026 |
| U.S. Social Core Equity 2 Portfolio | 1,741 | 0.02% | $3.88K | 0.00% | Jul 31, 2026 |
| U.S. Core Equity 2 Portfolio | 1,710 | 0.02% | $3.81K | 0.00% | Jul 31, 2026 |
| Omni Small-Cap Value Fund | 1,500 | 0.01% | $3.23K | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Joshua R. Disbrow | Chief Executive Officer, Director | 237,203 | 2.18% | Jul 30, 2026 |
| Greg Pyszczymuka | Chief Commercial Officer | 56,102 | 0.52% | Jul 30, 2026 |
| Jarrett Disbrow | Chief Business Officer | 76,568 | 0.70% | Jul 30, 2026 |
| Ryan J. Selhorn | Chief Financial Officer | 74,743 | 0.69% | Jul 30, 2026 |
| Vivian H. Liu | Director | 29,825 | 0.27% | Jul 30, 2026 |
| Carl Dockery | Director | 31,202 | 0.29% | Jul 30, 2026 |
| John Donofrio Jr. | Director | 23,762 | 0.22% | Jul 30, 2026 |
| Abhinav Jain | Director | 29,500 | 0.27% | Jul 30, 2026 |
| Nantahala Capital Management, LLC | 10% owner | 1,086,812 | 10.00% | Jun 9, 2025 |
| Daniel Mack | 10% owner | – | – | Jun 9, 2025 |
| Wilmot B. Harkey | 10% owner | – | – | Jun 9, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Ryan J. Selhorn Chief Financial Officer | Jul 28, 2026 | Award | +25,000 | – | – | 74,743 |
| Jarrett Disbrow Chief Business Officer | Jul 28, 2026 | Award | +15,000 | – | – | 76,568 |
| Abhinav Jain Director | Jul 28, 2026 | Award | +10,000 | – | – | 29,500 |
| John Donofrio Jr. Director | Jul 28, 2026 | Award | +10,000 | – | – | 23,762 |
| Joshua R. Disbrow Chief Executive Officer, Director | Jul 28, 2026 | Award | +30,000 | – | – | 237,203 |
| Greg Pyszczymuka Chief Commercial Officer | Jul 28, 2026 | Award | +20,000 | – | – | 56,102 |
| Carl Dockery Director | Jul 28, 2026 | Award | +10,000 | – | – | 31,152 |
| Vivian H. Liu Director | Jul 28, 2026 | Award | +10,000 | – | – | 29,825 |
| Greg Pyszczymuka Chief Commercial Officer | Oct 3, 2025 | Award | +12,500 | – | – | 36,102 |
| Vivian H. Liu Director | Oct 3, 2025 | Award | +10,000 | – | – | 19,825 |
| Ryan J. Selhorn Chief Financial Officer | Oct 3, 2025 | Award | +17,500 | – | – | 49,743 |
| Ryan J. Selhorn Chief Financial Officer | Oct 3, 2025 | Award | +16,243 | – | – | 32,243 |
| Carl Dockery Director | Oct 3, 2025 | Award | +10,000 | – | – | 20,440 |
| Joshua R. Disbrow Chief Executive Officer, Director | Oct 3, 2025 | Award | +22,500 | – | – | 207,203 |
| Joshua R. Disbrow Chief Executive Officer, Director | Oct 3, 2025 | Award | +31,446 | – | – | 184,703 |
| John Donofrio Jr. Director | Oct 3, 2025 | Award | +10,000 | – | – | 13,762 |
| Abhinav Jain Director | Oct 3, 2025 | Award | +10,000 | – | – | 19,500 |
| Jarrett Disbrow Chief Business Officer | Oct 3, 2025 | Award | +19,606 | – | – | 49,068 |
| Jarrett Disbrow Chief Business Officer | Oct 3, 2025 | Award | +12,500 | – | – | 61,568 |
| Joshua R. Disbrow Chief Executive Officer | Jun 9, 2025 | Buy | +66,666 | $1.50 | $100.00K | 153,257 |
| Jarrett Disbrow Chief Business Officer | Jun 9, 2025 | Buy | +16,666 | $1.50 | $25.00K | 29,462 |
| Greg Pyszczymuka Chief Commercial Officer | Mar 31, 2025 | Option exercise | +209 | – | – | 23,602 |
| Joshua R. Disbrow Chief Executive Officer | Feb 28, 2025 | Buy | +15,000 | $1.30 | $19.50K | 86,591 |
| Ryan J. Selhorn Chief Financial Officer | Feb 5, 2025 | Option exercise | +105 | – | – | 16,000 |
| Greg Pyszczymuka Chief Commercial Officer | Dec 31, 2024 | Option exercise | +208 | – | – | 23,393 |
| Ryan J. Selhorn Chief Financial Officer | Nov 11, 2024 | Award | +14,000 | – | – | 15,895 |
| Vivian H. Liu Director | Nov 6, 2024 | Award | +1,500 | – | – | 9,825 |
| Abhinav Jain Director | Nov 6, 2024 | Award | +1,500 | – | – | 9,500 |
| Carl Dockery Director | Nov 6, 2024 | Award | +1,500 | – | – | 10,440 |
| John Donofrio Jr. Director | Nov 6, 2024 | Award | +1,500 | – | – | 3,762 |
| Greg Pyszczymuka Chief Commercial Officer | Sep 30, 2024 | Option exercise | +209 | – | – | 23,185 |
| Greg Pyszczymuka Chief Commercial Officer | Jun 30, 2024 | Option exercise | +208 | – | – | 22,976 |
| Greg Pyszczymuka Chief Commercial Officer | Mar 31, 2024 | Option exercise | +208 | – | – | 22,768 |
| Greg Pyszczymuka Chief Commercial Officer | Dec 31, 2023 | Option exercise | +209 | – | – | 22,560 |
| Greg Pyszczymuka Chief Commercial Officer | Sep 30, 2023 | Option exercise | +208 | – | – | 22,351 |
| Abhinav Jain Director | Aug 16, 2023 | Award | +6,500 | – | – | 8,000 |
| Vivian H. Liu Director | Aug 11, 2023 | Award | +1,500 | – | – | 8,325 |
| John Donofrio Jr. Director | Aug 11, 2023 | Award | +1,500 | – | – | 2,262 |
| Carl Dockery Director | Aug 11, 2023 | Award | +1,500 | – | – | 8,940 |
| Vivian H. Liu Director | Aug 11, 2023 | Award | +1,500 | – | – | 1,841 |
| Abhinav Jain Director | Aug 11, 2023 | Award | +1,500 | – | – | 1,500 |
| Greg Pyszczymuka Chief Commerical Officer | Jun 30, 2023 | Option exercise | +208 | – | – | 22,143 |
| Greg Pyszczymuka Chief Commerical Officer | Jun 16, 2023 | Buy | +12,000 | $1.87 | $22.44K | 21,935 |
| Joshua R. Disbrow Chief Executive Officer, Director | Jun 14, 2023 | Buy | +14,000 | $1.86 | $26.04K | 71,591 |
| Greg Pyszczymuka Chief Commerical Officer | Apr 25, 2023 | Option exercise | +833 | – | – | 9,935 |
| Vivian H. Liu Director | Feb 8, 2023 | Award | +6,500 | – | – | 6,825 |
| John Donofrio Jr. Director | Dec 21, 2022 | Returned to company | −187,804 | – | – | 15,267 |
| Carl Dockery Director | Dec 21, 2022 | Returned to company | −40,000 | – | – | 148,805 |
| Gary Cantrell Director | Dec 21, 2022 | Returned to company | −40,000 | – | – | 164,089 |
| Joshua R. Disbrow Chief Executive Officer, Director | Dec 20, 2022 | Returned to company | −80,000 | – | – | 1,151,877 |
| Joshua R. Disbrow Chief Executive Officer, Director | Dec 19, 2022 | Buy | +112,371 | $0.22 | $24.72K | 1,231,877 |
| Greg Pyszczymuka Chief Commercial Officer | Dec 19, 2022 | Buy | +100,000 | $0.24 | $24.00K | 182,056 |
| Mark K. Oki Chief Financial Officer | Nov 18, 2022 | Buy | +90,000 | $0.23 | $20.70K | 190,000 |
| Joshua R. Disbrow Chief Executive Officer, Director | Nov 18, 2022 | Buy | +222,000 | $0.24 | $53.28K | 1,119,506 |
| Joshua R. Disbrow Chief Executive Officer, Director | Nov 18, 2022 | Award | +222,000 | $0.24 | $53.28K | 1,119,506 |
| Mark K. Oki Chief Financial Officer | Nov 18, 2022 | Award | +90,000 | $0.23 | $20.70K | 190,000 |
| Vivian H. Liu Director | Jul 1, 2022 | Award | +6,500 | – | – | 6,500 |
| Mark K. Oki Chief Financial Officer | Jan 17, 2022 | Award | +100,000 | – | – | 100,000 |
| John Donofrio Jr. Director | Apr 16, 2021 | Award | +187,804 | – | – | 203,071 |
| Gary Cantrell Director | Apr 16, 2021 | Award | +187,804 | – | – | 204,089 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Aytu BioPharma's stock actually held short. Settlement fails (shares not delivered on time) peaked at 12,426 shares on Sep 23, 2026 over the last 90 days.
See a number that looks wrong?